Comparing tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy) Both drugs show promise not only in improving metabolic health, reducing hemaglobin A1C (hbA1C), and assisting with weight lossthe data also shows that they may reduce the likelihood of cardiovascular events such as heart attack or stroke and improve cardiovascular outcomes across the board
Its ability to mimic the hormone glucagon-like peptide-1 (GLP-1) is crucial in regulating appetite and food intake
Throw in GLP-1s, and you may be in for a wild gastrointestinal ride
Continuing to increase the dose or incur that expense can be counterproductive. Without insurance coverage, these medications can cost more than $1,000 per month, which can make long-term use difficult to justify for some patients especially if results are limited
Experimental models have shown that GLP-1R activation can improve cognitive function and reduce amyloid plaque burden, suggesting potential disease-modifying effects [12, 13]